: Analysts currently maintain a Strong Buy consensus.
As of April 2026, IGC Pharma (IGC) is generally viewed by analysts as a or Strong Buy . The stock is a high-risk, high-reward play centered on its late-stage Alzheimer's clinical trials. Analyst Sentiment and Price Targets igc stock buy or sell
: Ascendiant Capital Markets recently reiterated its Buy rating and raised the price target to $5.25, citing clinical progress as a major upcoming catalyst. IGC Pharma Inc (IGC) -2.52% today Closed: 03:00 • Disclaimer After hours: 07:00 Apr 29, 2026 Mkt cap$30.99M USD 52-wk high0.50 P/E ratio- 52-wk low0.24 Div yield- Key Buy Case (Bullish) Google's Finance Data : Analysts currently maintain a Strong Buy consensus